NCT01593371

Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients

Comparing Effects of Metformin and Pioglitazone on Regulation of Serum Adipokines in Newly Diagnosed Type 2 Diabetes Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 98 (actual)
• Sponsor: Tehran University of Medical Sciences · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin), are two major groups of hypoglycemic medications that while function via different pathways, are both effective in short- and long-term glycemic control . These medications diminish or at least delay long term micro- and macrovascular complications associated with prolonged insulin resistance although at different rates. The mechanisms by which this aim is achieved, nevertheless, remains largely unclear. With adipokines playing a key role in development of both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these substances by direct and indirect routes.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
DRUG	Pioglitazone	Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-10-01
• Completion: 2012-01-01
• First posted: 2012-05-08
• Last updated: 2012-05-09

Locations

1 site across 1 country: Iran